drugset / Trial / NCT06209580
AMT-253 in Patients With Advanced Solid Tumours
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.
Timeline
- Start
- 2024-01-31
- Primary completion
- 2026-04-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMT-253 | Unknown | — | Intravenous |